173 related articles for article (PubMed ID: 8425197)
1. Characterization of sarcoma cell lines from v-jun transgenic mice.
Marshall GM; Vanhamme L
Cancer Res; 1993 Feb; 53(3):622-6. PubMed ID: 8425197
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells.
Vanhamme L; Marshall GM; Schuh AC; Breitman ML; Vogt PK
Cancer Res; 1993 Feb; 53(3):615-21. PubMed ID: 8425196
[TBL] [Abstract][Full Text] [Related]
3. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele.
Bader AG; Hartl M; Bister K
Virology; 2000 Apr; 270(1):98-110. PubMed ID: 10772983
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle arises as a late event during development of wound sarcomas in v-jun transgenic mice.
Schuh AC; Keating SJ; Yeung MC; Breitman ML
Oncogene; 1992 Apr; 7(4):667-76. PubMed ID: 1314368
[TBL] [Abstract][Full Text] [Related]
5. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice.
Schuh AC; Keating SJ; Monteclaro FS; Vogt PK; Breitman ML
Nature; 1990 Aug; 346(6286):756-60. PubMed ID: 2167455
[TBL] [Abstract][Full Text] [Related]
6. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
Bader AG; Schneider ML; Bister K; Hartl M
Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
[TBL] [Abstract][Full Text] [Related]
7. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
Basso J; Briggs J; Findlay C; Bos T
Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
[TBL] [Abstract][Full Text] [Related]
8. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
9. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts.
Cohen SB; Waha A; Gelman IH; Vogt PK
Oncogene; 2001 Jan; 20(2):141-6. PubMed ID: 11313943
[TBL] [Abstract][Full Text] [Related]
10. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos.
Wang ZQ; Liang J; Schellander K; Wagner EF; Grigoriadis AE
Cancer Res; 1995 Dec; 55(24):6244-51. PubMed ID: 8521421
[TBL] [Abstract][Full Text] [Related]
11. Jun, the oncoprotein.
Vogt PK
Oncogene; 2001 Apr; 20(19):2365-77. PubMed ID: 11402333
[TBL] [Abstract][Full Text] [Related]
12. v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype.
Iacovoni JS; Cohen SB; Berg T; Vogt PK
Oncogene; 2004 Jul; 23(33):5703-6. PubMed ID: 15133497
[TBL] [Abstract][Full Text] [Related]
13. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
14. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis.
Schuh AC; Theodorescu D; Shalaby F; Breitman ML
Cell Growth Differ; 1993 Mar; 4(3):177-84. PubMed ID: 8466856
[TBL] [Abstract][Full Text] [Related]
15. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
Hadman M; Loo M; Bos TJ
Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933
[TBL] [Abstract][Full Text] [Related]
16. Two distinct target cells for v-jun mediated wound tumorigenesis.
Shalaby F; Schuh AC; Breitman ML
Oncogene; 1994 Sep; 9(9):2579-88. PubMed ID: 8058321
[TBL] [Abstract][Full Text] [Related]
17. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors.
Kraemer M; Tournaire R; Dejong V; Montreau N; Briane D; Derbin C; Binétruy B
Cell Growth Differ; 1999 Mar; 10(3):193-200. PubMed ID: 10099833
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors.
Vial E; Perez S; Castellazzi M
Oncogene; 2000 Oct; 19(43):5020-9. PubMed ID: 11042689
[TBL] [Abstract][Full Text] [Related]
19. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
[TBL] [Abstract][Full Text] [Related]
20. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells.
Li J; Johnson TA; Hanson LA; Beer DG
Mol Carcinog; 1996 Aug; 16(4):213-20. PubMed ID: 8784464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
